HLA-A∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HLA-A∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses

Published:2021-12 Issue:13 Volume:37 Page:110167
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Nesterenko Pavlo A.,McLaughlin Jami,Tsai Brandon L.,Burton Sojo Giselle,Cheng Donghui,Zhao Daniel,Mao Zhiyuan,Bangayan Nathanael J.,Obusan Matthew B.,Su Yapeng,Ng Rachel H.,Chour William,Xie Jingyi,Li Yan-Ruide,Lee Derek,Noguchi Miyako,Carmona Camille,Phillips John W.,Kim Jocelyn T.,Yang Lili,Heath James R.,Boutros Paul C.,Witte Owen N.

Funder

National Cancer Institute

W M Keck Foundation

Broad Stem Cell Research Center

Biomedical Advanced Research and Development Authority

Andy Hill CARE Fund

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference67 articles.

1. Basic local alignment search tool;Altschul;J. Mol. Biol.,1990

2. Longitudinal analysis of humoral immunity against SARS-CoV-2 spike in convalescent individuals up to 8 months post-symptom onset;Anand;Cell Rep. Med,2021

3. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data;Reynisson;Nucleic Acids Res.,2020

4. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N. Engl. J. Med.,2021

5. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy;Basar;Cell Rep,2021

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence;Science Translational Medicine;2024-06-12

2. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects;Expert Opinion on Investigational Drugs;2024-04-30

3. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials;Viruses;2024-03-31

4. Defining T cell receptor repertoires using nanovial-based binding and functional screening;Proceedings of the National Academy of Sciences;2024-03-27

5. Identification of Phytochemicals from Arabian Peninsula Medicinal Plants as Strong Binders to SARS-CoV-2 Proteases (3CLPro and PLPro) by Molecular Docking and Dynamic Simulation Studies;Molecules;2024-02-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3